Januvia Generics Arrive In India
MSD Defends Its Turf As Sitagliptin Looks To Unseat Teneligliptin, Vildagliptin
Executive Summary
A wave of cut-price sitagliptin generics is seen hitting the Indian market with expiry of the patent on Merck’s Januvia, a product that has had a hugely eventful journey over the years including fending off pre-expiry challengers. Will the originator respond with price cuts?
You may also be interested in...
What’s Next? Five Things To Look Out For In April
Generics Bulletin previews the biggest events and changes for industry in the coming month.
Jamp To Offer Canadian Sitagliptin, Sandoz Bags Fixed-Dose Combo
An important mono- and adjunct therapy for diabetes patients now has generic competition in Canada, where an estimated 10% of the population are said to have been diagnosed with type 1 or type 2 diabetes.
Viatris Loses US Challenge To Januvia And Janumet Patents
Viatris’ attempts to deliver US generic versions of sitagliptin and sitagliptin/metformin ahead of patent expiry has failed for now, with an unfavorable judgment from a district court in West Virginia. More than 20 ANDA sponsors have opted to settle litigation with originator Merck.